Timing matters: clinical outcomes of early sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure
Abstract
Acute heart failure (AHF) remains associated with high short-term mortality and rehospitalization despite advances in therapy. Sodium–glucose cotransporter2 inhibitors (SGLT2i) provide robust cardiovascular benefits in heart failure, but their efficacy and safety when initiated during AHF hospitalization are less well established.
Following a systematic search of five databases, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of the initiation of dapagliflozin or empagliflozin during hospitalization for AHF, in addition to standard therapy. Primary outcomes were all-cause mortality and heart failure hospitalization (HFH). Secondary outcomes included all-cause mortality at 1-month, cardiovascular death, serious adverse events leading to drug discontinuation, acute kidney injury (AKI), hypotension, hypoglycemia, and diabetic ketoacidosis. Data were pooled using inverse variance random-effects models.
Eight RCTs including 3596 patients (1817 SGLT2i; 1779 control) were analyzed. SGLT2i initiation in AHF significantly reduced all-cause mortality (RR 0.63, 95% CI 0.46–0.85; P = 0.003; I² = 0%). No significant reduction was observed for HFH (RR 0.86, 95% CI 0.69–1.07; P = 0.78; I² = 0%). All-cause mortality at 1 month and cardiovascular death, did not differ significantly between groups. Pooled analyses showed no excess risk of hypotension, hypoglycemia, AKI or ketoacidosis.
Initiation of SGLT2i during…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.